UC HEALTH LINE: Temporary Heat Solutions Can Cause Serious Health Problems
We see at least one fatality or near death every winter because of carbon monoxide poisoning and portable heaters, says Thats because some portable heaters emit carbon monoxide (CO), a gas that cannot be seen or smelled. When used indoors, without proper ventilation, CO becomes the silent killer. While carbon monoxide poisoning is often associated with a faulty furnace or letting the car run in an enclosed garage, people should also realize that many portable heaters emit the gas as well. CO is released by any device that burns a fuel such as gasoline, kerosene, wood or propane, and when not properly ventilated can build to seriously dangerous levels for human exposure. This is not the case with electric heat. Symptoms of CO poisoning include fatigue, dizziness, headache, shortness of breath, nausea and mental confusion. Exposure to high enough levels can cause loss of consciousness and also death. Use of these portable heating devices in places with poor ventilation can lead to serious consequences from CO. Unfortunately, the signs of CO poisoning are subtle initially and are often confused for the flu, says Sean Collins, also an emergency department physician at UH and a fellow faculty member with Baxter at the According to the U.S. Consumer Product Safety Commission, when winters cold months bear down people are more apt to use portable heaters indoors, as supplemental heat or as a sole source of heat. The commissions latest figures estimate that more than 150 people die each year from CO poisoning associated with consumer products. Although extremely high levels of CO have deadly potential for most anyone, according to the commission those most susceptible are individuals with heart disease or chronic respiratory illness, fetuses, infants and young children. Cautionary information:
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.